#United States #New York #Class Action #Levi Korsinsky #Unicycive Therapeutics

Investors Alert: Class Action Lawsuit for Unicycive Therapeutics, Inc.

Levi & Korsinsky, LLP has announced a significant development for shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) who have suffered financial losses. The firm is inviting those impacted by alleged securities fraud to participate in a class action lawsuit. The legal action pertains to events that occurred between March 29, 2024, and June 27, 2025, during which various misstatements and omissions were made by the company and its executives.

Understanding the Class Action

The essence of this lawsuit centers around claims that Unicycive's leadership overstated the company's preparation and capacity to meet the FDA’s manufacturing compliance requirements. Furthermore, they allegedly exaggerated the potential for regulatory approval of their new drug application for oxylanthanum carbonate. These misleading public statements have been said to have led investors to make decisions that resulted in significant financial losses.

If you are a shareholder who lost money on Unicycive Therapeutics during the specified period, you may be eligible to join the lawsuit. The deadline to act is October 14, 2025, providing a limited window for affected individuals to step forward.

No Financial Burden for Participants

A compelling aspect of this class action is that it comes at no cost to participants. Any class member who qualifies does not have to incur upfront fees or make any out-of-pocket payments to be part of the lawsuit. This is an opportunity for investors to potentially recoup losses without financial risk, emphasizing the commitment of Levi & Korsinsky to represent shareholder interests.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has built a fortified reputation over the last 20 years, having secured hundreds of millions of dollars for investors through successful litigation strategies. Their experienced team specializes in complex securities litigation, making them adept at navigating class action lawsuits effectively. The firm has consistently ranked among the top 50 securities litigation firms in the United States, showcasing its track record of achievement and reliability.

What Investors Should Do Next

If you believe you are eligible to join the class action lawsuit against Unicycive Therapeutics, it is important to act swiftly. Interested investors should reach out to Joseph E. Levi, Esq. or another member of the Levi & Korsinsky team. You can contact them via email or by calling (212) 363-7500. In addition, a convenient online submission form is available for those looking to express their interest in joining the case.

The legal landscape surrounding securities fraud can be complex, but it’s crucial for investors to be informed about their rights and the actions they can take to seek justice. By joining this class action, shareholders not only take a stand against corporate misconduct but also enhance their chances of receiving compensation for their losses. Remember, timing is essential, so if you’ve faced losses with Unicycive Therapeutics, make your voice heard before the approaching deadline.

In summary, the ongoing class action lawsuit coordinated by Levi & Korsinsky for Unicycive Therapeutics represents an important step for shareholders seeking accountability and recompense for investments made under misleading pretenses. The call to action is clear: act now, explore your options, and connect with experienced legal representation to navigate this significant issue successfully.